gvtcx

Type 1 Diabetes Med-Tech Commercial Strategy

NHS England Published 6 Mar 2023 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£90,000
Statuscomplete
Category (CPV) 79411100
Deadline10 Feb 2023
Contract start13 Feb 2023
Contract end31 Mar 2023
Procedureselective
SME suitableNo
OCIDocds-b5fd17-486e2b9d-d727-47d2-8ea8-f06e58a22351

Award

SupplierValueDateStatus
DELOITTE LLP £90,000 24 Feb 2023 active

description

Identifying the best approach for the NHS in relation to absorbing the cost impact of the initial recommendations stemming from the NICE MTA undertaken for Type 1 Diabetes hybrid closed-loop medical technology

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
6 Mar 2023 Award (award) · 78545f00-3e63-43ac-b55f-f87807003f41-621599

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.